Definium Therapeutics - Common Shares (DFTX) closed at $33.00 on November 12, 2026, down 4.3% from the previous close, on volume of 1,121,927 shares (30-day average 1,770,496).
Data as of November 12, 2026.
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Oct 30, 2026 | Call Spread | 19-Mar-2738 : 48 C | 1,000 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 12, 2026. See the 10 largest for 30, 60 and 90 days
U.S. funding to support studies into psychedelic drug ibogaine in PTSD
Seeking Alpha News (Thu, 12-Nov 12:47 PM ET)
TipRanks (Thu, 12-Nov 7:50 AM ET)
Definium Therapeutics (DFTX) Receives a Buy from Wells Fargo
TipRanks (Wed, 11-Nov 7:25 AM ET)
DEA looks to increase legal psychedelics production for medical research
Seeking Alpha News (Tue, 10-Nov 10:45 AM ET)
TipRanks (Tue, 10-Nov 8:05 AM ET)
Oppenheimer Keeps Their Buy Rating on Definium Therapeutics (DFTX)
TipRanks (Tue, 10-Nov 7:55 AM ET)
Definium Therapeutics (DFTX) Receives a Rating Update from a Top Analyst
TipRanks (Tue, 10-Nov 7:35 AM ET)
TipRanks (Tue, 10-Nov 7:31 AM ET)
TipRanks (Tue, 10-Nov 7:01 AM ET)
Bank of America Securities Reaffirms Their Buy Rating on Definium Therapeutics (DFTX)
TipRanks (Tue, 10-Nov 5:35 AM ET)
Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company operates in one reportable segment relating to the research and development of the company's neurological drug development platform.
Definium Therapeutics - Common Shares trades on the NASDAQ stock market under the symbol DFTX.
As of November 13, 2026, DFTX stock price declined to $31.82 with 138,072 million shares trading.
DFTX has a beta of 0.12, meaning it tends to be less sensitive to market movements. DFTX has a correlation of 0.00 to the broad based SPY ETF.
DFTX has a market cap of $4.36 billion. This is considered a Mid Cap stock.
The top ETF exchange traded funds that DFTX belongs to (by Net Assets): IWM, VXF, IWO, IBB, VTWO.
DFTX support price is $31.70 and resistance is $34.30 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that DFTX shares will trade within this expected range on the day.
